Literature DB >> 16891918

Peripheral musculoskeletal manifestations in polymyalgia rheumatica.

Federico Ceccato1, Susana G Roverano, Silvia Papasidero, Alejandra Barrionuevo, Oscar L Rillo, Sergio O Paira.   

Abstract

OBJECTIVES: The objectives of this study were to evaluate the frequency and characteristics of the peripheral musculoskeletal manifestations in polymyalgia rheumatica (PMR), evaluate if PMR with peripheral synovitis represents a subset with a more severe disease, and examine for clinical and laboratory characteristics at onset of PMR that might later predict rheumatoid arthritis (RA). PATIENTS AND METHODS: Patients were diagnosed with PMR according to the 1982 Chuang criteria. Patients were followed up between 1990 and 2002. The following musculoskeletal manifestations at onset and during the follow up were considered: peripheral synovitis, distal extremity swelling with pitting edema, carpal tunnel syndrome, and distal tenosynovitis.
RESULTS: Thirty-eight of the 74 patients (51%) showed distal musculoskeletal symptoms: 29 (39%) had peripheral synovitis, 4 (5%) presented pitting edema, 4 (5%) experienced carpal tunnel syndrome, and one (1.3%) had distal tenosynovitis. These manifestations resolved completely after corticosteroid therapy was initiated. Peripheral synovitis was oligoarticular and often transient. The joints most frequently involved were the wrist, metacarpophalangeal, and knee. Erythrocyte sedimentation rate (ESR) was normal in 7 patients. When comparing patients with PMR with and without peripheral synovitis, no statistically significant differences were found in the studied variables. Through the first year of follow up, 7 patients fulfilled the American College of Rheumatology 1987 criteria for RA, 2 patients developed giant cell arteritis, and 3 had associated malignancy. Patients who developed RA had statistically significantly increased presence of persistent synovitis and a smaller decrease in mean ESR after treatment with corticosteroids.
CONCLUSION: Fifty-one percent of the patients with PMR presented distal musculoskeletal manifestations, with peripheral synovitis being the most frequent one. Patients with PMR with peripheral synovitis did not represent a high-risk subgroup with more severe disease. Seven patients who developed criteria for seronegative RA within the first year of follow up had presented statistically significant persistent synovitis compared with those who continued as PMR and also showed a smaller initial decrease in mean ESR after steroid treatment was initiated. The absence of persistent arthritis and the benign course of the arthritis permit the distinction of PMR from other inflammatory arthropathies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16891918     DOI: 10.1097/01.rhu.0000231381.21179.e6

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  7 in total

Review 1.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 2.  Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Authors:  Tanaz A Kermani; Kenneth J Warrington
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-02       Impact factor: 5.346

3.  Polymyalgia rheumatica: A case series from Colombia and analysis of Latin America.

Authors:  Carlos Enrique Toro-Gutiérrez; Carlos A Cañas; Rubén D Mantilla; Santiago Beltrán; Vivian Pastrana-Gonzalez; Milly J Vecino; Mónica Rodriguez-Jimenez; Manuel Rojas
Journal:  J Transl Autoimmun       Date:  2021-08-21

Review 4.  Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.

Authors:  Dario Camellino; Eric L Matteson; Frank Buttgereit; Christian Dejaco
Journal:  Nat Rev Rheumatol       Date:  2020-08-05       Impact factor: 20.543

Review 5.  Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus.

Authors:  Christian Dejaco; Christina Duftner; Marco A Cimmino; Bhaskar Dasgupta; Carlo Salvarani; Cynthia S Crowson; Hilal Maradit-Kremers; Andrew Hutchings; Eric L Matteson; Michael Schirmer
Journal:  Ann Rheum Dis       Date:  2010-11-19       Impact factor: 19.103

6.  Thrombocytosis as a prognostic factor in polymyalgia rheumatica: characteristics determined from cluster analysis.

Authors:  Keigo Hayashi; Keiji Ohashi; Haruki Watanabe; Ken-Ei Sada; Kenta Shidahara; Yosuke Asano; Sumie Hiramatsu Asano; Yuriko Yamamura; Yoshia Miyawaki; Michiko Morishita; Yoshinori Matsumoto; Tomoko Kawabata; Jun Wada
Journal:  Ther Adv Musculoskelet Dis       Date:  2019-07-18       Impact factor: 5.346

7.  Imaging Findings in Patients with Immune Checkpoint Inhibitor-Induced Arthritis.

Authors:  Andrés Ponce; Beatriz Frade-Sosa; Juan C Sarmiento-Monroy; Nuria Sapena; Julio Ramírez; Ana Belén Azuaga; Rosa Morlà; Virginia Ruiz-Esquide; Juan D Cañete; Raimon Sanmartí; José A Gómez-Puerta
Journal:  Diagnostics (Basel)       Date:  2022-08-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.